Carisma receives Nasdaq delisting notice for MVLS, MVPHS, bid price non-compliance

Carisma Therapeutics Inc.

Nasdaq notified Carisma on April 10, 2025, of delisting for failing to maintain $50M MVLS by April 8, 2025 compliance deadline.
Company also failed $15M MVPHS rule; granted 180 days until October 7, 2025, to regain compliance.
Existing bid price non-compliance (below $1.00) has compliance period through July 7, 2025.
Carisma plans to request a hearing before Nasdaq Panel to stay delisting; no assurance of extension.
Company considering all options but cannot guarantee regaining compliance with any listing rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.